Incomplete Brown-Séquard syndrome secondary to acenocoumarol-induced hematomyelia: A case report

Table 1 Laboratory findings

Laboratory panel	Result
Coagulation panel
PT (%)	30
INR	2.6
Thyroid panel
TSH (mU/L)	0.418
FT3 (pg/mL)	1.83
FT4 (ng/dL)	1.3
Anti-TPO (IU/mL)	3
Infectious panel
HIV 1/2	Negative
HBsAg	0.32 S/CO (negative)
Anti-HCV	0.66 S/CO (negative)
Protein electrophoresis
Albumin (%)	56.5
α1-globulins (%)	3.6
α2-globulins (%)	14.4
β1-globulins (%)	6.5
β2-globulins (%)	7.7
γ-globulins (%)	11.3
A/G ratio	1.3
Autoimmune panel
ANA	< 1:160
Anti-dsDNA (IU/mL)	8.6
MPO (RU/mL)	1.5
RF (IU/mL)	< 20
Tumor markers
CEA (ng/mL)	2
AFP (ng/mL)	4
CA-125 (U/mL)	11.8
CA-19-9 (U/mL)	< 2.06
CA-15-3 (U/mL)	13

PT: Prothrombin time; INR: International normalized ratio; FT3: Free triiodothyronine; FT4: Thyroxine; TPO: Thyroid peroxidase; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; ANA: Antinuclear antibody; MPO: Myeloperoxidase; RF: Rheumatoid factor; CEA: Carcinoembryonic antigen; AFP: Alpha fetoprotein; CA: Cancer antigen.

Table 2 Prognostic factors and outcome predictors in intramedullary spinal cord hemorrhage

Category	Favorable prognostic factors	Poor prognostic factors
Clinical presentation	Incomplete neurological deficit	Complete sensorimotor paralysis
	Preserved ambulation	Early loss of ambulation
	Slow or non-progressive symptoms	Rapid neurological deterioration
Timing	Early MRI diagnosis (< 24-48 hours)	Delayed diagnosis
Radiological features	Small, focal hemorrhage	Long-segment cord involvement
	Limited cord edema	Severe edema and mass effect
Etiology	Isolated anticoagulant-related bleed	Vascular malformation or tumor
Management	Prompt cessation/reversal of anticoagulation	Ongoing anticoagulation
	Neurological stability under conservative treatment	Recurrent bleeding
Patient factors	Younger age, fewer comorbidities	Advanced age, hypertension, diabetes, heart failure

MRI: Magnetic resonance imaging.